Effectiveness and cost-effectiveness of thrombolysis in submassive pulmonary embolism

Archives of Internal Medicine

Volumn 167, Issue 1, 2007, Pages 74-80

  Perlroth, Daniella J ^a   Sanders, Gillian D ^b   Gould, Michael K ^a,c  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; CATECHOLAMINE; HEPARIN;

ARTICLE; ARTIFICIAL VENTILATION; BLEEDING; BRAIN HEMORRHAGE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG SAFETY; EMBOLECTOMY; FIBRINOLYTIC THERAPY; HEALTH CARE COST; HEART RIGHT VENTRICLE FUNCTION; HUMAN; LUNG EMBOLISM; LUNG HEMODYNAMICS; MAJOR CLINICAL STUDY; MONOTHERAPY; MORTALITY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SENSITIVITY ANALYSIS; TREATMENT OUTCOME;

COST-BENEFIT ANALYSIS; DRUG THERAPY, COMBINATION; FIBRINOLYTIC AGENTS; HEALTH CARE COSTS; HEPARIN; HUMANS; PULMONARY EMBOLISM; RANDOMIZED CONTROLLED TRIALS; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 33846118260     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinte.167.1.74     Document Type: Article

References (44)

1. Goldhaber SZ. Thrombolysis in pulmonary embolism: a debatable indication. Thromb Haemost. 2001;86:444-451.
2. Dalen JE, Alpert JS, Hirsch J. Thrombolytic therapy for pulmonary embolism: is it effective? is it safe? when is it indicated? Arch Intern Med. 1997;157:2550-2556.
3. Urokinase in pulmonary embolism. Lancet. 1973;301:1427-1428.
4. Goldhaber SZ, Haire WD, Feldstein ML, et al. Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion. Lancet. 1993;341:507-511.
5. Come PC, Kim D, Parker JA, Goldhaber SZ, Braunwald E, Markis JE. Early reversal of right ventricular dysfunction in patients with acute pulmonary embolism after treatment with intravenous tissue plasminogen activator. J Am Coll Cardiol. 1987;10:971-978.
6. Dalla-Volta S, Palla A, Santolicandro A, et al. PAIMS 2: alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism: Plasminogen Activator Italian Multicenter Study 2. J Am Coll Cardiol. 1992;20:520-526.
7. Konstantinides S, Tiede N, Geibel A, Olschewski M, Just H, Kasper W. Comparison of alteplase versus heparin for resolution of major pulmonary embolism. Am J Cardiol. 1998;82:966-970.
8. Jerjes-Sanchez C, Ramirez-Rivera A, de Lourdes Garcia M, et al. Streptokinase and heparin versus heparin alone in massive pulmonary embolism: a randomized controlled trial. J Thromb Thrombolysis. 1995;2:227-229.
9. Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet. 1999;353:1386-1389.
10. Kasper W, Konstantinides S, Geibel A, et al. Management strategies and determinants of outcome in acute major pulmonary embolism: results of a multicenter registry. J Am Coll Cardiol. 1997;30:1165-1171.
11. Grifoni S, Olivotto I, Cecchini P, et al. Short-term clinical outcome of patients with acute pulmonary embolism, normal blood pressure, and echocardiographic right ventricular dysfunction. Circulation. 2000;101:2817-2822.
12. Goldhaber SZ. Thrombolysis for pulmonary embolism. N Engl J Med. 2002;347:1131-1132.
13. Konstantinides S, Geibel A, Olschewski M, et al. Association between thrombolytic treatment and the prognosis of hemodynamically stable patients with major pulmonary embolism: results of a multicenter registry. Circulation. 1997;96:882-888.
14. Konstantinides S, Geibel A, Heusel G, Heinrich F, Kasper W. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med. 2002;347:1143-1150.
15. Naimark D, Krahn MD, Naglie G, Redelmeier DA, Detsky AS. Primer on medical decision analysis, V: working with Markov processes. Med Decis Making. 1997;17:152-159.
16. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA. 1996;276:1253-1258.
17. GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329:673-682.
18. Simonneau G, Sors H, Charbonnier B, et al; THESEE Study Group [Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire]. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. N Engl J Med. 1997;337:663-669.
19. Sors H, Pacouret G, Azarian R, Meyer G, Charbonnier B, Simonneau G. Hemodynamic effects of bolus vs 2-h infusion of alteplase in acute massive pulmonary embolism: a randomized controlled multicenter trial. Chest. 1994;106:712-717.
20. Carson JL, Kelley MA, Duff A, et al. The clinical course of pulmonary embolism. N Engl J Med. 1992;326:1240-1245.
21. Arcasoy SM, Kreit JW. Thrombolytic therapy of pulmonary embolism: a comprehensive review of current evidence. Chest. 1999;115:1695-1707.
22. Gore JM, Granger CB, Simoons ML, et al. Stroke after thrombolysis: mortality and functional outcomes in the GUSTO-I trial: Global Use of Strategies to Open Occluded Coronary Arteries. Circulation. 1995;92:2811-2818.
23. Mark DB, Hlatky MA, Califf RM, et al. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction [published correction appears in N Engl J Med. 1995;333:267]. N Engl J Med. 1995;332:1418-1424.
24. American Medical Association. Physicians' Current Procedural Terminology. Chicago, Ill: American Medical Association; 2003.
25. American Medical Association. Medicare's Resource Based Relative Value Units. Chicago, Ill: American Medical Association; 2002.
26. Medical Economics. Drug Topics Red Book. Montvale, NJ: Thomson Healthcare; 2003.
27. Solucient LLC. Length of Stay by Diagnosis, United States. Evanston, Ill: Solucient LLC; 2002.
28. Centers for Medicare and Medicaid Services. Medicare provider analysis and review inpatient hospital fiscal year 2000. http://cms.hhs.gov/statistics/ medpar/default.asp. Accessed December 4, 2002.
29. Mahaffey KW, Granger CB, Sloan MA, et al. Neurosurgical evacuation of intracranial hemorrhage after thrombolytic therapy for acute myocardial infarction: experience from the GUSTO-I trial: Global Utilization of Streptokinase and tissue-plasminogen activator (tPA) for Occluded Coronary Arteries. Am Heart J. 1999;138:493-499.
30. Bell CM, Chapman RH, Stone PW, Sandberg EA, Neumann PJ. An off-the-shelf help list: a comprehensive catalog of preference scores from published costutility analyses. Med Decis Making. 2001;21:288-294.
31. Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators. A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med. 1997;337:1118-1123.
32. Sarasin FP, Eckman MH. Management and prevention of thromboembolic events in patients with cancer-related hypercoagulable states: a risky business. J Gen Intern Med. 1993;8:476-486.
33. Gage BF, Cardinalli AB, Albers GW, Owens DK. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. JAMA. 1995;274:1839-1845.
34. Fryback DG, Dasbach EJ, Klein R, et al. The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors. Med Decis Making. 1993;13:89-102.
35. Lee TT, Solomon NA, Heidenreich PA, Oehlert J, Garber AM. Cost-effectiveness of screening for carotid stenosis in asymptomatic persons. Ann Intern Med. 1997;126:337-346.
36. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of costeffectiveness acceptability curves. Health Econ. 2001;10:779-787.
37. Ashton RW, Daniels CE, Ryu JH. Thrombolytic therapy in patients with submassive pulmonary embolism [letter]. N Engl J Med. 2003;348:357-359.
38. Gunn NA, Tierney LM Jr. Thrombolytic therapy in patients with submassive pulmonary embolism [letter]. N Engl J Med. 2003;348:357-359.
39. Konstantinides S, Geibel A, Olschewski M, et al. Importance of cardiac troponins I and T in risk stratification of patients with acute pulmonary embolism. Circulation. 2002;106:1263-1268.
40. Giannitsis E, Muller-Bardorff M, Kurowski V, et al. Independent prognostic value of cardiac troponin T in patients with confirmed pulmonary embolism. Circulation. 2000;102:211-217.
41. Meyer T, Binder L, Hruska N, Luthe H, Buchwald AB. Cardiac troponin I elevation in acute pulmonary embolism is associated with right ventricular dysfunction. J Am Coll Cardiol. 2000;36:1632-1636.
42. Aujesky D, Obrosky DS, Stone RA, et al. Derivation and validation of a prognostic model for pulmonary embolism. Am J Respir Crit Care Med. 2005;172:1041-1046.
43. Aujesky D, Obrosky DS, Stone RA, et al. A prediction rule to identify low-risk patients with pulmonary embolism. Arch Intern Med. 2006;166:169-175.
44. Sharma GV, Folland ED, McIntyre KM, Sasahara AA. Long-term benefit of thrombolytic therapy in patients with pulmonary embolism. Vasc Med. 2000;5:91-95.